- Home
- GSIW vs ADXN Comparison
GSIW vs ADXN Comparison
Compare GSIW & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | ADXN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Hong Kong | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 8.6M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GSIW | ADXN |
|---|---|---|
| Price | $14.24 | $3.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.5K | ★ 103.4K |
| Earning Date | 08-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $3.30 |
| 52 Week High | $38.55 | $11.97 |
Technical Indicators
Market Signals| Indicator | GSIW | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 31.02 |
| Support Level | $13.46 | N/A |
| Resistance Level | $18.03 | $7.37 |
| Average True Range (ATR) | 1.71 | 0.34 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 28.28 | 12.03 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.